The biotech mapping thousands of hidden therapeutic clues
Think drug discovery is slow? This biotech is moving faster, smarter and deeper – by asking the question that no one else has.
List view / Grid view
Think drug discovery is slow? This biotech is moving faster, smarter and deeper – by asking the question that no one else has.
As the lab–data science divide continues, Ian Kerman looks ahead to a future of deeper collaboration – one where shared skills, smarter tools and a shift in mindset could finally break down the barriers. In this second interview, he shares his vision, practical ideas and advice for the next generation…
Researchers at POSTECH have developed a new 3D brain model that closely mimics the structure and function of human brain tissue – marking a major advance in early disease detection.
Fauna Bio has launched Fauna Brain™, a powerful new AI platform that leverages the company’s expertise in comparative genomics to accelerate drug target discovery.
Researchers at Tokyo University of Science have identified three new enzyme families that degrade the complex bacterial carbohydrate β-1,2-glucan – offering new opportunities for enzyme engineering.
A practicing surgeon turned biotech CEO is developing a novel pain medicine that could sidestep the failures of both opioids and paracetamol.
Scientists have developed a simple- 3D mouse tissue model to study how the nose regenerates smell-sensing neurons. The goal is to create an organoid system that can be used to screen potential therapies for smell loss.
A new study at Science Tokyo has developed patient-derived organoids to better understand and combat resistance in oesophageal squamous cell carcinoma (ESCC).
Researchers at the University of Alabama have identified reelin, a glycoprotein known for its role in brain development, as a key regulator of neurons in the brain's reward centre, potentially making way for targeted therapies against cocaine use.
Stanford scientists have successfully grown heart and liver organoids that include functioning blood vessels. This breakthrough overcomes a major size and maturity barrier, which could advance disease modelling and regenerative therapies in the future.
What if you could actually see where a drug travels in the body down to the cellular level. Find out how mass spectrometry imaging (MSI) is making that possible – reshaping drug development from the inside out.
Shift Bioscience has announced new aging research, highlighting the discovery of SB000. This novel single-gene target reverses cellular aging without activating dangerous pluripotency pathways.
Lab scientists and data scientists often speak different languages and that miscommunication can slow down important research. In this interview, Ian Kerman shares how his team is working to break down those walls and spark better collaboration.
EPFL scientists have engineered virus-inspired DNA aptamers that bind infection targets with record selectivity. This innovation could change how we diagnose and treat infectious diseases.
Researchers at the University of Oklahoma have found a way to improve drugs by adding just one carbon atom. This simple change could speed up drug discovery and lower costs.